Molecular Devices LLC
San Jose, CA Part of Beckman Coulter, Inc.
- UEI
- L64RUJ7LC8T9
- CAGE
- 0H297
- Primary NAICS
- 334516 Analytical Laboratory Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Danaher Corporation, ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Beckman Coulter, Inc. · Brea, CA
Z4DRFM3LMJB8
-
Parent
Beckman Coulter, Inc. · Brea, CA
Z4DRFM3LMJB8
- SAM.gov registration date
- Physical address
- 3860 N First St, San Jose, CA 95134, USA
- Website
- moleculardevices.com
- Founded
- 1983
- Employees
- 251-1K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $1,325,388 |
| FY2025 | $722,173 |
| FY2024 | $1,801,277 |
| FY2023 | $1,940,678 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $780,981 | |
| 2 | Department of Agriculture | $423,561 | |
| 3 | Department of Veterans Affairs | $60,174 | |
| 4 | Department of the Army | $38,518 | |
| 5 | Uniformed Services University of the Health Sciences | $22,154 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Roche Diagnostics Corporation | 75N91020F00003 | $565,356 | |
| Leidos, Inc. | FA807521F0006 | $31,500 |
Similar vendors
About the company
Molecular Devices LLC, a San Jose, California-based subsidiary of Beckman Coulter, Inc., manufactures and maintains laboratory analytical instruments, microplate readers, high-content imaging systems, and electrophysiology equipment for federal biomedical research agencies as a prime contractor, competing entirely on a full-and-open, non-set-aside basis as an original equipment manufacturer (OEM).
Molecular Devices operates in analytical laboratory instrument manufacturing (549 awards) and electronic equipment repair and maintenance (258 awards) across two dominant PSC categories: laboratory equipment and supplies (395 awards) and maintenance/repair/rebuild of instruments and lab equipment (366 awards). The vendor's concrete federal work centers on delivering SpectraMax microplate reader systems (absorbance, fluorescence, luminescence, and multimode platforms), FLIPR high-throughput cellular screening instruments, ImageXpress confocal and high-content imaging systems, electrophysiology amplifiers and digitizers (Multiclamp and Digidata platforms), and QPIX automated colony pickers, alongside preventative maintenance, onsite performance assurance, parts replacement, software upgrades, and technical support for these proprietary systems. Representative recent awards include a $294,438 four-year maintenance agreement with the National Institute of Neurological Disorders and Stroke for an ImageXpress Micro Confocal system (awarded November 2024); a $488,794.70 definitive contract with CDC Pittsburgh for laboratory equipment (August 2024); a $742,212.70 five-year service agreement with the National Center for Advancing Translational Sciences for confocal high-content imaging system maintenance (February 2024, subsequently terminated for convenience); and a $605,098.90 high-content screening system purchase order from FDA's Center for Food Safety and Applied Nutrition (January 2023).
Customer concentration is heavily skewed toward the National Institutes of Health and its component institutes. The top five funding agencies account for 28 percent of recent awards by count and 46 percent by combined potential value. The National Center for Advancing Translational Sciences leads by potential value (15 awards, $6.2 million), followed by FDA (46 awards, $4.2 million), CDC Pittsburgh (65 awards, $4 million), NIAID (78 awards, $2.4 million), and the National Institute on Drug Abuse (30 awards, $2.3 million). By award frequency, the National Cancer Institute leads (81 awards, $1.2 million), followed closely by NIAID (78 awards, $2.4 million) and CDC Pittsburgh. The two rankings diverge notably: NCATS places fewer orders but larger maintenance and service contracts, while NCI places numerous smaller service agreements and equipment orders.
Across 1,170 total prime and sub awards spanning 1986 to September 2026, activity has remained flat to modestly declining in recent years — 37 awards in 2022, 34 in 2023, 41 in 2024, 20 in 2025, and 12 through September 2026. Fifteen awards with combined potential value of $1.4 million reach ultimate completion within the next twenty-four months, representing moderate recompete exposure. The vendor operates as a pure prime contractor (100% of awards as prime, with only 2 sub-award records across the portfolio), indicating no reliance on subcontractor delivery teams and no feeder relationship into larger primes. SCI-reportable federal service contract invoicing totaled $240 thousand in FY2024 with zero FTEs assigned in that fiscal year, reflecting the vendor's reliance on purchase-order-based goods and short-term maintenance contracts above the SCI reporting threshold, which exclude products and are therefore not representative of Molecular Devices' true federal instrument and service revenue. The vendor's top parent vehicles include an indefinite delivery contract (DAAD1300D5010, 5 task orders), a blanket purchase agreement (36C24818A0024, 3 task orders, $286 thousand), and two GSA federal supply schedules (GS00F2478A and GS24F3061G, 2–3 task orders each), indicating some leverage of standing vehicles but predominance of direct purchase orders issued by individual NIH institutes, FDA centers, and CDC facilities.
Molecular Devices' competitive posture is anchored to its status as sole-source OEM for proprietary instrument platforms and factory-trained service. The vendor's award descriptions consistently cite non-competitive, sole-source authority (FAR 6.302-1) and original equipment manufacturer justifications, meaning federal customers award maintenance and upgrade work directly without competitive solicitation. This OEM moat — combined with the technical lock-in of existing Paradigm, FLIPR, ImageXpress, SpectraMax, and Multiclamp installations across 90 distinct federal agencies — insulates Molecular Devices from general competition but ties its growth to federal research funding levels and replacement cycles for specialized bioanalytical equipment.
Quick answers
Is Molecular Devices LLC registered in SAM.gov?
Yes. Molecular Devices LLC's SAM.gov registration is active through December 31, 2026.
How much has Molecular Devices LLC received in federal contracts?
Federal contracts obligated $722,173 to Molecular Devices LLC in fiscal year 2025 and $5,789,516 in fiscal years 2023 through 2027.
How does Molecular Devices LLC rank among federal contractors?
Molecular Devices LLC's parent company, Danaher Corporation, ranked #4 in PSC J066, #7 in PSC 6640 and #7 in NAICS 334516 in FY2025.
What is Molecular Devices LLC's most recent federal award?
Molecular Devices LLC's most recent federal contract award is Factory service, maintenance, and parts purchase order for paradigm machines at niaid vaccine immunology program lab in… (75N98026P01658), from Office of Logisitics and Acquisition Operations (NIH), on September 30, 2026.
On GovTribe
See Molecular Devices LLC's full federal record
- Federal contract awards
- IDV awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors